You are here

DERMAXON LLC

Company Information
Address
6610 JUSTIN CT
MISSOULA, MT 59803-2969
United States


http://dermaxon.com/

Information

UEI: R33ESK4L9GG3

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    Amount: $295,423.00

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (at ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Novel therapeutic target to combat cutaneous lupus

    Amount: $298,132.00

    Project Summary / Abstract: Chronic auto-inflammatory skin diseases such as cutaneous lupus erythematosus (CLE) affect millions of Americans with limited therapeutic options currently available, creat ...

    STTRPhase I2021Department of Health and Human Services National Institutes of Health
  3. Topical selective T-type blockers for the treatment of pruritus

    Amount: $224,999.00

    Project SummaryAbstractPruritusalso called itchis the most frequent dermatological symptom in the US with up toof Americans being affectedPruritic stimuli are detected by a subset of nociceptive neuro ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  4. Topical selective T-type blockers for the treatment of neuropathic pain

    Amount: $228,479.00

    Project SummaryAbstract Paclitaxel is widely used throughout the field of oncology with indications for the treatment of a number of solid tumorsThe most commonly reported neurotoxic effect of paclita ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis

    Amount: $1,499,868.00

    Project SummaryAbstract DermaXon s project goal is to develop efficacious substrate based and highly selective inhibitors of CYPsthe enzymes responsible or retinoic acidRAmetabolism in the epidermisfo ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  6. Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis

    Amount: $215,640.00

    Project Summary Abstract DermaXon s project goal is to develop efficacious novel selective inhibitors of CYP A for the topical treatment of ichthyosis Congenital ichthyosis is a family of heredit ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  7. Inhibition of retinoic acid metabolism for reversal of cognitive deficits in AD

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and ultimately fatal neurodegenerative disease that affects more than five million people in the USA. Currently ther ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government